Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx,...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of MDWD is 31 and suggests 69% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell